

The logo for the European Bioanalysis Forum (EBF) is located in the top right corner of the slide. It consists of the letters 'EBF' in a white, sans-serif font, positioned above a white curved line that arches to the right. Below the curve, the words 'European Bioanalysis Forum' are written in a smaller, white, sans-serif font, stacked vertically.

EBF

European  
Bioanalysis  
Forum

# Regulatory Panel Discussion

***Presenter: Jo Goodman and Michaela Golob  
on behalf of EBF***

Immunogenicity Focus Workshop  
27<sup>th</sup> September 2016  
Lisbon

# Questions

- Thanks to everyone that submitted questions
- Selected common themes
- If your question fell off....ask it anyway !!
- Use of breaks for further discussion

# Clinical Analysis

1. What constitutes a “pivotal trial”?
2. What constitutes high risk?
  - How is the risk assessment handled and when?
3. What is the minimum required for early phases?
4. Timing of sample analysis (batched vs. real time)?
5. Interpretation of results – how is this handled and what is needed?
6. What is an acceptable threshold of inconclusive results?

# Assays

1. At what clinical stage should a validated assay be available?
2. When are the draft EMA and FDA guideline/guidance documents on assays expected to be finalised?
3. What is the expected sensitivity for NAb assays?
4. In cases where there is a substantial amount of circulating metabolite would this change the immunogenicity assay testing strategy?
5. Is a medium positive control necessary and does it add value?
  - Could a low PC control be the only one that is critical?